Osta Biotechnologies Inc. is pleased to announce that on April 1, 2010, it has closed its previously announced ``bought deal'' private placement of 8,400,000 units at a price of $0.06 per unit, for gross proceeds to Osta of $504,000.
125156
Osta announces closing of private placement
132097
Patient Safety Technologies closes on $2.485 million in equity financing
110824
BioStart closing for good
116083
Rosetta Genomics completes direct offering;
31607
Linedata finalises acquisition of CapitalStream
83483
Crombie REIT announces closing of public unit offering
115014
Pfizer buying FoldRx for undisclosed amount
32116
PF Chang's to go private in $1.1 billion deal
17783
Public shareholdings spread
112080
Solutia initiates stock offering
155340
Agreement to acquire claims closes
24400
$9.8 million awarded for stem cell research
83682
Autonomy expected to sell for $10 billion
166711
Monsanto expecting $150 million charge
41423
Dainippon Sumitomo Pharma to buy US bio-venture
11595
Agnico-Eagle announces closing of US$290 million private placement
40508
The ovarian cancer drug market will more than triple over the next decade, increasing from $460 million in 2011 to $1.4 billion in 2021